L&C Bio’s ‘Re2O’ Emerges as a Leading K-Medical Tour Procedure Within One Year of Launch
Surging global demand drives rapid adoption across domestic and international medical sectors – L&C Bio (KOSDAQ: 290650, Co-CEOs Hwan-Chul Lee and Jae-Ho Lee), a leading company in human tissue-based regenerative medicine, announced that its premium regenerative solution Re2O (ReCM, ECM: Extra Cellular Matrix) has rapidly emerged as a signature K-Medical tour procedure among international customers […]